Targeting both GD2 and B7-H3 using bispecific antibody improves tumor selectivity for GD2-positive tumors.

Zachary T Rosenkrans Amy K ErbeNathan B ClemonsArika S Feils Yadira Medina-GuevaraJustin J JefferyTodd E Barnhart Johnathan W Engle Paul M Sondel Reinier Hernandez

Published in: bioRxiv : the preprint server for biology (2024)

The GD2-B7-H3 targeting bispecific antibodies successfully improved selectivity to cells expressing both antigens. This approach should address the severe toxicities associated with GD2-targeting therapies by reducing off-tumor GD2 binding in nerves. Continued improvements in bispecific antibody technologies will continue to transform the therapeutic biologics landscape.

Keyphrases

cancer therapy
induced apoptosis
single cell
cell cycle arrest
signaling pathway
cell proliferation
transcription factor
cell death
endoplasmic reticulum stress